BRCA2 and neoplasm: Unfortunately, PC appears to be a poorly immunogenic tumor characterized by the presence of a powerful immunosuppressive tumor microenvironment, which hinders substantial response to immunotherapy [11], whereas potential benefits of therapeutic strategies indicated in cases with specific molecular aberrations, such as defective mismatch repair or BRCA1/BRCA2 mutations, are limited to small subgroups of patients [12].